OCT 13, 2015 4:51 PM PDT

Cytokine IL-17 Could Be New Drug Target for Psoriasis

WRITTEN BY: Kara Marker

Psoriasis is a chronic autoimmune disorder causing inflammation of the skin. The exact cause is unknown, but scientists do know that a large volume of inflammatory cells are released as an immune response, inflaming skin and creating a vicious cycle of inflammation.

As knowledge surrounding T helper cell types increases, scientists have discovered more potential drug targets for treating psoriasis. Cytokine interleukin 17 and others in the IL-17 pathway are the newest drug targets for psoriasis therapies.
About the Author
Master's (MA/MS/Other)
I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
Loading Comments...